Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.
|Motif Bio Update on NDA Submission for Iclaprim|
March 20, 2018
|Motif Bio to present at upcoming investor and scientific conferences|
March 19, 2018
|Motif Bio to Present Iclaprim Data at ECCMID 2018|
February 21, 2018